Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease

Zerbib, F; Bruley des Varannes, S; Roman, S; Tutuian, R; Galmiche, J-P; Mion, F; Tack, J; Malfertheiner, P; Keywood, C (2011). Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 33(8), pp. 911-21. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2011.04596.x

Full text not available from this repository. (Request a copy)

ADX10059, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, has been shown to reduce gastro-oesophageal reflux events and oesophageal acid exposure in patients with gastro-oesophageal reflux disease (GERD) and healthy subjects.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Tutuian, Radu

ISSN:

0269-2813

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:23

Last Modified:

17 Mar 2015 21:01

Publisher DOI:

10.1111/j.1365-2036.2011.04596.x

PubMed ID:

21320138

Web of Science ID:

000288515800006

URI:

https://boris.unibe.ch/id/eprint/7761 (FactScience: 213087)

Actions (login required)

Edit item Edit item
Provide Feedback